National Blood Authority website

Annual Report Home

Table of Contents

Image: Annual Report Cover

National Blood Authority Australia – Annual Report 2008–2009

Part Six. Appendices

Appendix 4. Plasma and recombinant products supplied under contract in 2008–09

List of products supplied under the Plasma Products Agreement
Supplier Product type/trade name Clinical use approved under the National Blood Arrangements
CSL Limited Albumin  
  Albumex® 4 Used to treat hypovolaemia arising from shock, surgery or multiple organ failure
  Albumex® 20 Used to treat patients suffering extensive burns or shock due to blood loss, or kidney or liver disease
  Immunoglobulins  
  Hyperimmune globulins Used to prevent a specific infection such as tetanus, hepatitis B, Zoster or cytomegalovirus
  Intragam® P Used to reduce susceptibility to infections and manage many immune system disorders
  Clotting factors  
  Biostate® Used to treat Factor VIII deficiency, known as haemophilia A
  MonoFIX®-VF Used to treat patients who have Factor IX deficiency, known as haemophilia B or Christmas disease
  Prothrombinex®-VF Used to manage some bleeding disorders (concentrated clotting factors) and warfarin reversal
  Thrombotrol®-VF Used to manage an inherited condition wherein a patient’s blood clots too quickly
List of imported IVIg products
Supplier Product type/trade name Clinical use approved under the National Blood Arrangements
CSL Limited Sandoglobulin® Used to reduce susceptibility to infections and manage many immune system disorders
Octapharma Australia Pty Ltd Octagam® Used to reduce susceptibility to infections and manage many immune system disorders
List of imported rare bleeding and blood disorder plasma products
Supplier Product type/trade name Clinical use approved under the National Blood Arrangements
Baxter Healthcare Pty Ltd Anti Inhibitor Coagulant Complex Concentrates/FEIBA® Used to treat bleeding episodes including surgical interventions in haemophilia A and B patients with inhibitors
Baxter Healthcare Pty Ltd Protein C/Ceprotin® Used to treat congenital Protein C deficiency
Baxter Healthcare Pty Ltd FVII concentrate Used to treat Factor VII deficiency
Baxter Healthcare Pty Ltd WinRho Used to prevent a potentially fatal form of anaemia in newborn babies of Rh (D) negative mothers
CSL Limited FXI/BPL Factor XI Used to treat people with Factor XI deficiency (sometimes called haemophilia C)
CSL Limited FXIII/Fibrogammin®  P Used to treat people with Factor XIII deficiency
CSL Limited Rh (D) Immunoglobulin/WinRho® Used to prevent haemolytic disease of the newborn (HDNB), a potentially fatal form of anaemia in newborn babies of Rh (D) negative mothers
List of imported rare bleeding and blood disorder recombinant products
Supplier Product type/trade name Clinical use approved under the National Blood Arrangements
Novo Nordisk Pharmaceuticals Pty Ltd rFVIIa/NovoSeven® Used to treat bleeding episodes including surgical intervention in haemophilia A or B patients with inhibitors to Factor VIII or Factor IX; also used to treat complex bleeding episodes in surgery, trauma and septicaemia
Baxter Healthcare Pty Ltd rFVIII/Recombinate® Used to treat Factor VIII deficiency, known as haemophilia A
Baxter Healthcare Pty Ltd rFVIII/Advate® Used to treat Factor VIII deficiency, known as haemophilia A
Wyeth Australia Pty Ltd rFVIII/Refacto® Used to treat Factor VIII deficiency, known as haemophilia A
Wyeth Australia Pty Ltd rFIX/BeneFIX® Used to treat patients who have Factor IX deficiency, known as haemophilia B or Christmas disease

Top of Page

Previous Page | Next Page